Log In
BCIQ
Print this Print this
 

AVR-01

  Manage Alerts
Collapse Summary General Information
Company Avrobio Inc.
DescriptionAutologous T cells modified ex vivo to express IL-12
Molecular Target Interleukin-12 (IL-12)
Mechanism of Action 
Therapeutic ModalityGene therapy
Latest Stage of DevelopmentPhase I
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myeloid leukemia (AML)
Regulatory Designation
PartnerUniversity Health Network

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/18/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today